ANJAC HEALTH & BEAUTY STRENGTHENS ITS PRESENCE IN THE HEALTH AND PHARMA SECTOR AND UNVEILS TWO INNOVATIVE TECHNOLOGIES AT CPHI FRANKFURT
AT THE CPHI FRANKFURT TRADE FAIR, THE FRENCH INDUSTRIAL GROUP ANJAC HEALTH & BEAUTY CONFIRMS ITS STRATEGIC POSITIONING IN THE HEALTH AND PHARMA SECTOR. THE FAMILY-OWNED COMPANY, ALREADY RECOGNISED FOR ITS EXPERTISE IN FORMULATION, MANUFACTURING AND PACKAGING FOR BEAUTY, HEALTH AND DIETARY SUPPLEMENTS, IS PRESENTING TWO MAJOR INNOVATIONS THERE: CICALYTE AND EMULPRO.
Health, a strategic growth driver
Driven by eight of its subsidiaries – Chemineau, Feltor, Cosmetix West, Pillar5 Pharma, Eurowipes, Shadeline, Innovi and Roval – the health‑pharma business now accounts for nearly 30% of the Group’s revenue. This division is emerging as a key development area, supported by future investments and acquisitions in nutrition and dietary supplements, particularly in Europe.
At CPHI, Anjac is highlighting four priority areas: ENT and respiratory health, with recognised expertise in local solutions (sprays, mouthwashes, etc.) and new therapeutic perspectives; dermatology, through an integrated approach covering prevention, treatment and dermocosmetics; women’s health, with solutions to support the different hormonal phases of life; and nutrition and dietary supplements, with a focus on prevention and long‑term well‑being.
Cicalyte, a bioactive electrolyte solution
The first innovation presented in Frankfurt, Cicalyte is an electrolyte solution inspired by extracellular fluid, with anti‑inflammatory and healing properties. Designed to restore mucosal health, it offers an alternative to conventional saline solutions, which are often irritating.
Cicalyte can be used in the management of rhinosinusal and bronchial conditions, nasopharyngitis, sinusitis, allergies or post‑operative care, and can be incorporated into various nasal or bronchial products, whether hygiene solutions or treatments containing active ingredients such as corticosteroids or antihistamines.
A new generation of high‑tolerance emulsion with Emulpro
The second flagship technology, Emulpro, is a micro‑droplet emulsion that ensures optimal penetration of active ingredients while preserving the skin microbiome. Ultra‑tolerant, it helps limit the risk of irritation, dryness or alteration of the skin barrier.
Versatile, Emulpro is suitable for several routes of administration (topical, mucosal, oral, nasal) and for a wide range of textures. It paves the way for new solutions in dermatology and women’s health, particularly for atopic skin or intimate dryness issues. A first ready‑to‑use application, Emulpro‑Atopic Dermatitis, is already available for partner brands.
“Anjac is asserting its strong ambitions in the health‑pharma segment. This is reflected in current and future investments in R&D for differentiated formulas and the launch of new ranges. Our objective remains unchanged: to offer a high level of service to our customers, to meet people’s evolving needs and to provide products at the forefront of innovation and performance,” says Emmanuelle Labbé Raillard, Chief Strategic Growth Officer of Anjac Group.
La rédaction, PHARMACOS MEDIA